ArticleCureus2024
Rituximab Safety Profile: A Seven-Year Retrospective Analysis From Southern India.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to analyze the pattern, severity, and outcomes of adverse drug reactions (ADRs) associated with rituximab use reported to a regional pharmacovigilance center in Kerala, India.
methodsThis retrospective study analyzed rituximab-associated ADRs reported from 2017 to 2023. ADRs were assessed using the WHO-UMC criteria for causality and the Modified Hartwig Siegel Scale for severity.
resultsA total of 74 patients reported ADRs, with 49 being female. The majority (27 patients) were in the 51- to 60-year age group. Malignancies accounted for 58 cases of rituximab use. Most ADRs (69 cases) occurred with the first dose, with infusion reactions being the most common. Causality assessment revealed that 48 ADRs were probably related to rituximab. Severity analysis using the Modified Hartwig Siegel Scale showed that 67 ADRs were level two (mild), while two were level seven (severe). The majority of patients (72) recovered. However, rituximab-induced lung disease, observed in two cases, was associated with higher mortality.
conclusionRituximab demonstrated an acceptable safety profile, with most ADRs being non-serious and manageable. The high recovery rate reflects effective ADR management. However, the potential for serious complications, particularly rituximab-induced lung disease, highlights the need for vigilant monitoring, especially during the first infusions. These findings enhance understanding of rituximab's real-world safety profile and underscore the importance of standardized protocols for ADR mitigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.